NCT06254599View on ClinicalTrials.gov

A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

255

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

May 1, 2026

Study Completion Date

May 1, 2027

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

SY-3505 Capsules

A third-generation ALK tyrosine kinase inhibitor

DRUG

Crizotinib Capsules

An oral ALK tyrosine kinase inhibitor

Trial Locations (1)

100021

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Shouyao Holdings (Beijing) Co. LTD

OTHER